The NADPH oxidase NOX2 controls glutamate release: A novel mechanism involved in psychosis-like ketamine responses

Journal of Neuroscience

Volumn 30, Issue 34, 2010, Pages 11317-11325

  Sorce, Silvia ^a,b   Schiavone, Stefania ^a,b,c   Tucci, Paolo ^c   Colaianna, Marilena ^c   Jaquet, Vincent ^a,b   Cuomo, Vincenzo ^d   Dubois Dauphin, Michel ^a,b   Trabace, Luigia ^c   Krause, Karl Heinz ^a,b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY OF FOGGIA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; GLUTAMIC ACID; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; PARVALBUMIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; MALE; MOUSE; NEUROTRANSMITTER RELEASE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSYCHOSIS; RECEPTOR DOWN REGULATION;

ANIMALS; DISEASE MODELS, ANIMAL; GLUTAMIC ACID; KETAMINE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; NADPH OXIDASE; PREFRONTAL CORTEX; PSYCHOSES, SUBSTANCE-INDUCED; REACTIVE OXYGEN SPECIES;

EID: 77956121499     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.1491-10.2010     Document Type: Article

References (62)

1. 2. J Neurosci 23:2744-2750.
2. Bao L, Avshalumov MV, Patel JC, Lee CR, Miller EW, Chang CJ, Rice ME (2009) Mitochondria are the source of hydrogen peroxide for dynamic brain-cell signaling. J Neurosci 29:9002-9010.
3. Bassareo V, Di Chiara G (1997) Differential influence of associative and nonassociative learning mechanisms on the responsiveness of prefrontal and accumbal dopamine transmission to food stimuli in rats fed ad libitum. J Neurosci 17:851-861. (Pubitemid 27024596)
4. Bedard K, Krause KH (2007) The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87:245-313. (Pubitemid 46209993)
5. Behrens MM, Ali SS, Dao DN, Lucero J, Shekhtman G, Quick KL, Dugan LL (2007) Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science 318:1645-1647. (Pubitemid 350233667)
6. Behrens MM, Ali SS, Dugan LL (2008) Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia. J Neurosci 28:13957-13966.
7. Belforte JE, Zsiros V, Sklar ER, Jiang Z, Yu G, Li Y, Quinlan EM, Nakazawa K (2010) Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci 13:76-83.
8. Beneyto M, Meador-Woodruff JH (2008) Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychopharmacology 33:2175-2186. (Pubitemid 351992080)
9. Bubeníková-Valesová V, Horácek J, Vrajová M, Höschl C (2008) Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci Biobehav Rev 32:1014-1023.
10. Castane A, Artigas F, Bortolozzi A (2008) The absence of 5-HT(1A) receptors has minor effects on dopamine but not serotonin release evoked by MK-801 in mice prefrontal cortex. Psychopharmacology (Berl) 200:281-290.
11. Cochran SM, Kennedy M, McKerchar CE, Steward LJ, Pratt JA, Morris BJ (2003) Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Neuropsychopharmacology 28:265-275.
12. Coitinho AS, Dietrich MO, Hoffmann A, Dall'Igna OP, Souza DO, Martins VR, Brentani RR, Izquierdo I, Lara DR (2002) Decreased hyperlocomotion induced by MK-801, but not amphetamine and caffeine in mice lacking cellular prion protein (PrP(C)). Brain Res Mol Brain Res 107:190-194. (Pubitemid 35335537)
13. de Oliveira L, Spiazzi CM, Bortolin T, Canever L, Petronilho F, Mina FG, Dal-Pizzol F, Quevedo J, Zugno AI (2009) Different sub-anesthetic doses of ketamine increase oxidative stress in the brain of rats. Prog Neuropsychopharmacol Biol Psychiatry 33:1003-1008.
14. Dietrich-Muszalska A, Olas B (2009) Isoprostenes as indicators of oxidative stress in schizophrenia. World J Biol Psychiatry 10:27-33.
15. Ellison G (1995) The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias. Brain Res Brain Res Rev 20:250-267.
16. Farber NB (2003) The NMDA receptor hypofunction model of psychosis. Ann NY Acad Sci 1003:119-130.
17. Gainetdinov RR, Mohn AR, Caron MG (2001) Genetic animal models: focus on schizophrenia. Trends Neurosci 24:527-533.
18. Gascón S, Sobrado M, Roda JM, Rodríguez-Peña A, Díaz-Guerra M (2008) Excitotoxicity and focal cerebral ischemia induce truncation of the NR2A and NR2B subunits of the NMDA receptor and cleavage of the scaffolding protein PSD-95. Mol Psychiatry 13:99-114.
19. Gunduz-Bruce H (2009) The acute effects of NMDA antagonism: from the rodent to the human brain. Brain Res Rev 60:279-286.
20. Harte MK, Powell SB, Swerdlow NR, Geyer MA, Reynolds GP (2007) Deficits in parvalbumin and calbindin immunoreactive cells in the hippocampus of isolation reared rats. J Neural Transm 114:893-898.
21. Hashimoto K (2009) Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 61:105-123.
22. Hayase T, Yamamoto Y, Yamamoto K (2006) Behavioral effects of ketamine and toxic interactions with psychostimulants. BMC Neurosci 7:25. (Pubitemid 43833579)
23. Homayoun H, Moghaddam B (2007) NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 27:11496-11500. (Pubitemid 350006886)
24. Imre G, Fokkema DS, Den Boer JA, Ter Horst GJ (2006) Dose-response characteristics of ketamine effect on locomotion, cognitive function and central neuronal activity. Brain Res Bull 69:338-345.
25. Irifune M, Shimizu T, Nomoto M (1991) Ketamine-induced hyperlocomotion associated with alteration of presynaptic components of dopamine neurons in the nucleus accumbens of mice. Pharmacol Biochem Behav 40:399-407.
26. Irifune M, Sato T, Kamata Y, Nishikawa T, Nomoto M, Fukuda T, Kawahara M (1998) Inhibition by diazepam of ketamine-induced hyperlocomotion and dopamine turnover in mice. Can J Anaesth 45:471-478. (Pubitemid 28365517)
27. Jaquet V, Scapozza L, Clark R, Krause KH, Lambeth JD (2009) Small molecule NOX inhibitors: ROS-generating NADPH oxidases as therapeutic targets. Antioxid Redox Signal 11:2535-2552.
28. Jentsch JD, Roth RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201-225. (Pubitemid 29067401)
29. Khan MM, Evans DR, Gunna V, Scheffer RE, Parikh VV, Mahadik SP (2002) Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res 58:1-10. (Pubitemid 35287278)
30. Kinney JW, Davis CN, Tabarean I, Conti B, Bartfai T, Behrens MM (2006) A specific role for NR2A-containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons. J Neurosci 26:1604-1615. (Pubitemid 43237031)
31. Kishida KT, Klann E (2007) Sources and targets of reactive oxygen species in synaptic plasticity and memory. Antioxid Redox Signal 9:233-244. (Pubitemid 46105422)
32. Kishida KT, Hoeffer CA, Hu D, Pao M, Holland SM, Klann E (2006) Synaptic plasticity deficits and mild memory impairments in mouse models of chronic granulomatous disease. Mol Cell Biol 26:5908-5920. (Pubitemid 44134344)
33. Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R (2003) NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl) 169:215-233. (Pubitemid 37264943)
34. Kume A, Dinauer MC (2000) Gene therapy for chronic granulomatous disease. J Lab Clin Med 135:122-128. (Pubitemid 30105070)
35. Lewis DA, Hashimoto T, Volk DW (2005) Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 6:312-324.
36. Maeng S, Zarate CA Jr (2007) The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr Psychiatry Rep 9:467-474. (Pubitemid 350284937)
37. Maeng S, Zarate CA Jr, Du J, Schloesser RJ, McCammon J, Chen G, Manji HK (2008) Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 63:349-352. (Pubitemid 351146651)
38. Mahadik SP, Mukherjee S, Scheffer R, Correnti EE, Mahadik JS (1998) Elevated plasma lipid peroxides at the onset of nonaffective psychosis. Biol Psychiatry 43:674-679. (Pubitemid 28222388)
39. Mathew SJ, Manji HK, Charney DS (2008) Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology 33: 2080-2092.
40. Mechri A, Saoud M, Khiari G, d'Amato T, Dalery J, Gaha L (2001) Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine (in French). Encephale 27:53-59. (Pubitemid 32234479)
41. Morrone LA, Rombolà L, Pelle C, Corasaniti MT, Zappettini S, Paudice P, Bonanno G, Bagetta G (2007) The essential oil of bergamot enhances the levels of amino acid neurotransmitters in the hippocampus of rat: implication of monoterpene hydrocarbons. Pharmacol Res 55:255-262. (Pubitemid 46518156)
42. Nanduri J, Yuan G, Kumar GK, Semenza GL, Prabhakar NR (2008) Transcriptional responses to intermittent hypoxia. Respir Physiol Neurobiol 164:277-281.
43. Olney JW, Newcomer JW, Farber NB (1999) NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 33:523-533.
44. Sansone M (1980) Influence of benzodiazepine tranquilizers on amphetamine-induced locomotor stimulation in mice. Psychopharmacology (Berl) 71:63-65. (Pubitemid 11226286)
45. Schäppi MG, Jaquet V, Belli DC, Krause KH (2008) Hyperinflammation in chronic granulomatous disease and anti-inflammatory role of the phagocyte NADPH oxidase. Semin Immunopathol 30:255-271.
46. Schiavone S, Sorce S, Dubois-Dauphin M, Jaquet V, Colaianna M, Zotti M, Cuomo V, Trabace L, Krause KH (2009) Involvement of NOX2 in the development of behavioral and pathologic alterations in isolated rats. Biol Psychiatry 66:384-392.
47. Sesack SR, Carr DB, Omelchenko N, Pinto A (2003) Anatomical substrates for glutamate-dopamine interactions: evidence for specificity of connections and extrasynaptic actions. Ann NY Acad Sci 1003:36-52. (Pubitemid 38083044)
48. Skolnick P, Popik P, Trullas R (2009) Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci 30:563-569.
49. Sorce S, Krause KH (2009) NOX enzymes in the central nervous system: from signaling to disease. Antioxid Redox Signal 11:2481-2504.
50. Spielewoy C, Biala G, Roubert C, Hamon M, Betancur C, Giros B (2001) Hypolocomotor effects of acute and daily d-amphetamine in mice lacking the dopamine transporter. Psychopharmacology (Berl) 159:2-9. (Pubitemid 34031244)
51. Sulzer D, Sonders MS, Poulsen NW, Galli A (2005) Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 75:406-433. (Pubitemid 40834286)
52. Trabace L, Kendrick KM, Castrignanò S, Colaianna M, De Giorgi A, Schiavone S, Lanni C, Cuomo V, Govoni S (2007) Soluble amyloid beta1-42 reduces dopamine levels in rat prefrontal cortex: relationship to nitric oxide. Neuroscience 147:652-663. (Pubitemid 46990646)
53. Tsai G, Coyle JT (2002) Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 42:165-179.
54. Uchihashi Y, Kuribara H, Isa Y, Morita T, Sato T (1994) The disruptive effects of ketamine on passive avoidance learning in mice: involvement of dopaminergic mechanism. Psychopharmacology (Berl) 116:40-44. (Pubitemid 24279595)
55. Violi F, Sanguigni V, Loffredo L, Carnevale R, Buchetti B, Finocchi A, Tesauro M, Rossi P, Pignatelli P (2006) Nox2 is determinant for ischemia-induced oxidative stress and arterial vasodilatation: a pilot study in patients with hereditary Nox2 deficiency. Arterioscler Thromb Vasc Biol 26:e131-e132. (Pubitemid 44305354)
56. Violi F, Sanguigni V, Carnevale R, Plebani A, Rossi P, Finocchi A, Pignata C, De Mattia D, Martire B, Pietrogrande MC, Martino S, Gambineri E, Soresina AR, Pignatelli P, Martino F, Basili S, Loffredo L (2009) Hereditary deficiency of gp91(phox) is associated with enhanced arterial dilatation: results of a multicenter study. Circulation 120:1616-1622.
57. Wu HY, Yuen EY, Lu YF, Matsushita M, Matsui H, Yan Z, Tomizawa K (2005) Regulation of N-methyl-D-aspartate receptors by calpain in cortical neurons. J Biol Chem 280:21588-21593.
58. Xi D, Keeler B, Zhang W, Houle JD, Gao WJ (2009) NMDA receptor subunit expression in GABAergic interneurons in the prefrontal cortex: application of laser microdissection technique. J Neurosci Methods 176:172-181.
59. Yao JK, Reddy RD, van Kammen DP (2001) Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 15:287-310. (Pubitemid 32337052)
60. Yashiro K, Philpot BD (2008) Regulation of NMDA receptor subunit expression and its implications for LTD, LTP, and metaplasticity. Neuropharmacology 55:1081-1094.
61. Zhang XY, Chen da C, Xiu MH, Wang F, Qi LY, Sun HQ, Chen S, He SC, Wu GY, Haile CN, Kosten TA, Lu L, Kosten TR (2009) The novel oxidative stress marker thioredoxin is increased in first-episode schizophrenic patients. Schizophr Res 113:151-157.
62. Zuo DY, Wu YL, Yao WX, Cao Y, Wu CF, Tanaka M (2007) Effect of MK-801 and ketamine on hydroxyl radical generation in the posterior cingulate and retrosplenial cortex of free-moving mice, as determined by in vivo microdialysis. Pharmacol Biochem Behav 86:1-7. (Pubitemid 46274964)